NCT04426474View on ClinicalTrials.gov

A Study of LY3502970 in Participants With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

October 8, 2020

Primary Completion Date

July 12, 2021

Study Completion Date

July 12, 2021

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

LY3502970

Administered orally.

DRUG

Placebo

Administered orally.

Trial Locations (6)

33014

Clinical Pharmacology of Miami, Hialeah

41460

Profil Institut für Stoffwechselforschung, Neuss

45417

Midwest Clinical Research Unit, Dayton

55116

Profil Mainz, Mainz

78229

Endeavor Clinical Trials, San Antonio

08053

Hassman Research Institute, Marlton

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04426474 - A Study of LY3502970 in Participants With Type 2 Diabetes | Biotech Hunter | Biotech Hunter